NVST vs. XRAY, FTRE, XENE, SHC, PRCT, IRTC, IDYA, JANX, PGNY, and HCM
Should you be buying Envista stock or one of its competitors? The main competitors of Envista include DENTSPLY SIRONA (XRAY), Fortrea (FTRE), Xenon Pharmaceuticals (XENE), Sotera Health (SHC), PROCEPT BioRobotics (PRCT), iRhythm Technologies (IRTC), IDEAYA Biosciences (IDYA), Janux Therapeutics (JANX), Progyny (PGNY), and HUTCHMED (HCM). These companies are all part of the "medical" sector.
Envista (NYSE:NVST) and DENTSPLY SIRONA (NASDAQ:XRAY) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.
In the previous week, DENTSPLY SIRONA had 2 more articles in the media than Envista. MarketBeat recorded 7 mentions for DENTSPLY SIRONA and 5 mentions for Envista. DENTSPLY SIRONA's average media sentiment score of 1.16 beat Envista's score of 0.75 indicating that DENTSPLY SIRONA is being referred to more favorably in the news media.
DENTSPLY SIRONA received 428 more outperform votes than Envista when rated by MarketBeat users. Likewise, 61.21% of users gave DENTSPLY SIRONA an outperform vote while only 39.44% of users gave Envista an outperform vote.
Envista has higher earnings, but lower revenue than DENTSPLY SIRONA. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.
Envista has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
95.7% of DENTSPLY SIRONA shares are owned by institutional investors. 1.3% of Envista shares are owned by company insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
DENTSPLY SIRONA has a net margin of -2.41% compared to Envista's net margin of -4.70%. DENTSPLY SIRONA's return on equity of 11.54% beat Envista's return on equity.
Envista currently has a consensus price target of $25.86, suggesting a potential upside of 36.70%. DENTSPLY SIRONA has a consensus price target of $35.22, suggesting a potential upside of 24.33%. Given Envista's higher probable upside, analysts plainly believe Envista is more favorable than DENTSPLY SIRONA.
Summary
DENTSPLY SIRONA beats Envista on 13 of the 18 factors compared between the two stocks.
Get Envista News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
